Abstract Search

ea0037ep475 | Diabetes (complications & therapy) | ECE2015

Glycaemic control and weight evolution in type 2 diabetic patients with dapagliflozina in addition to their previous treatment

de Linares Lidia Urbon Lopez , Soto Maria Cristina Crespo , Vina Marta Ventosa , Larumbre Concepcion Terroba , Monclus Claudia Martin , Martin Tomas Martin , Olmedo Luis Cuellar

Introduction: From November 2013 it is available in Spain a new drug to treat type 2 diabetes (DM2): dapagliflozina. The new mechanism of action consists in the inhibition of the sodiumglucose co transporters (SLGT2) inhibiting glucose reabsorption in the proximale tubule and increasing glucose excreted in the urine. Therefore hyperglycaemia decreases and so does weight as a consequence of glycosuria. This is a very convenient side effect since DM2 is highly associated w...

1 shares

ePoster

Endocrine Abstracts

Glycaemic control and weight evolution in type 2 diabetic patients with dapagliflozina in addition to their previous treatment

BiosciAbstracts